Evidence map›Paper›PMID 39982659›Full record

ArticleInternational urology and nephrology2025

Intravesical gemcitabine versus anthracyclines for primary and first recurrent non-muscle-invasive bladder cancer: a single-center retrospective study over 10 years.

Haobo Fan, Weiwu Chen, Wenhao Guo, Jiayu Han, Haoze Xie, Yanlan Yu, Guoqing Ding, Yicheng Chen

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Haobo FanDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Weiwu ChenDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Wenhao GuoDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Jiayu HanDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Haoze XieDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Yanlan YuDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Guoqing DingDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Yicheng ChenDepartment of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China. chenyicheng@zju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare intravesical instillation of gemcitabine and anthracyclines in the treatment of primary non-muscle-invasive bladder cancer (NMIBC), and to evaluate the effect of changing intravesical chemotherapy drugs on the the second recurrence of NMIBC.

methodPatients with NMIBC who underwent transurethral resection of bladder tumor (TURBT) for the first time in our center from January 2014 to December 2023 were enrolled. Kaplan-Meier method was used to analyze the recurrence-free survival (RFS) and progression-free survival (PFS), and COX regression was used to analyze the risk factors for recurrence.

result464 patients were included in the study (212 in the gemcitabine group and 252 in the anthracyclines group). Anthracyclines-treated patients had superior RFS compared to gemcitabine-treated patients (p = 0.006), but PFS did not differ significantly between the two groups (p = 0.654). After the first recurrence of NMIBC, patients who changed intravesical chemotherapy drugs had better RFS than those who kept the original chemotherapy drugs (p = 0.037). In terms of safety, the incidence of adverse events of pirarubicin was significantly higher than that of gemcitabine and epirubicin (55.2% vs 26.4% vs 36.2%, p < 0.001).

conclusionAnthracyclines are more effective than gemcitabine in preventing recurrence of primary NMIBC but with more adverse events. After the first recurrence of NMIBC, changing the drugs of intravesical chemotherapy can reduce the second recurrence of NMIBC.

Indexed as

AnthracyclinesAntimetabolites, AntineoplasticDeoxycytidineNeoplasm Recurrence, LocalUrinary Bladder NeoplasmsAdministration, IntravesicalAgedFemaleGemcitabineHumansMaleMiddle AgedNeoplasm InvasivenessNon-Muscle Invasive Bladder NeoplasmsRetrospective StudiesTime FactorsAnthracyclinesAntimetabolites, AntineoplasticDeoxycytidineGemcitabineAnthracyclinesBladder cancerGemcitabineIntravesical chemotherapy

Identifiers

PMID39982659

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.